Short answer
GeneDx Holdings Corp. (WGS) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Mark Gardner appointed President effective June 15, overseeing GeneDx lab and commercial operations.
GeneDx Holdings Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Mark Gardner appointed President effective June 15, overseeing GeneDx lab and commercial operations
- Leadership shift moves Bryan Dechairo toward product, technology and innovation initiatives
- Compensation includes $530,000 base salary, 65% target bonus, and $2,000,000 restricted stock unit grant
- RSUs vest in equal annual installments over four years, aligning retention with execution
- Change-in-control protection includes 12 months’ salary, one-times target bonus, healthcare continuation, and accelerated equity vesting
Item 7.01 · Regulation FD Disclosure
- Gardner appointed President, signaling a senior leadership transition at GeneDx
- Exhibit 99.1 contains the company’s press release and likely provides appointment rationale and background details
Item EX-99.1 · Exhibit EX-99.1
- Mark Gardner appointed President effective June 15, 2026, reporting to CEO Katherine Stueland
- Leadership change places commercial and operations execution under former Quest Diagnostics genomics executive
- Gardner brings nearly three decades across diagnostics, genomics, sequencing and healthcare technology
- Strategic priority: efficient scaling, stronger commercial execution and expanded genomic medicine leadership
- No compensation or financial guidance disclosed; execution outcomes remain subject to healthcare market and regulatory risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GeneDx Holdings Corp. 8-K filings
Get the next WGS 8-K as it lands
Follow WGS for push alerts, or ask the research agent what this filing means.